Bioavailability of Flucanazole
Candidiasis
About this trial
This is an interventional other trial for Candidiasis
Eligibility Criteria
Inclusion Criteria Male and females between the ages of 18 and 35 years
- Healthy Individual
- Able to swallow
Exclusion Criteria:
History or presence of significant:
- cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.
In addition, history or presence of:
alcoholism or drug abuse within the past year; hypersensitivity or idiosyncratic reaction to fluconazole or other azoles. Subjects who have used any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days prior to first dose.
Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 30 days prior to first dose.
Subjects who have been anormal diet during the 30 days prior to the first dosing.
Sites / Locations
- Sutphin Drugs
- Lifein Multi-Specialty Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Flucanazole
Diflucan
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition
The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Diflucan 40mgm/ml 35 ml Suspension and to measure AUC at 0, 1 , 4 , 8, 12, 16 , 20 and 24 hours Under Fed Condition